CLAIMS

1. A stable, liquid pharmaceutical formulation ~~comprising~~ interferon-beta, a stabilising amount of a ~~polyol~~, and a buffer capable of maintaining the pH of the ~~formulation~~ at a value between 3.0 and 4.0.

2. A liquid pharmaceutical formulation according to claim 1, wherein the polyol is mannitol.

3. A liquid pharmaceutical formulation according to ~~any of the claims 1 or 2~~ claim 1, in which interferon-beta is recombinant.

4. A liquid pharmaceutical formulation according to ~~any of the preceding claims~~ claim 1, in which interferon-beta is in a quantity between 0.6 and 1 MIU/ml.

5. A liquid pharmaceutical formulation according to ~~any of the preceding claims~~ claim 1, in which the buffer solution is acetate buffer.

6. A liquid pharmaceutical formulation according to claim 4, in which the buffer solution has a concentration of 0.01 M.

7. A liquid pharmaceutical formulation according to ~~any of the claims from 1 to 6~~ claim 1, which also comprises human albumin.

8. A liquid pharmaceutical formulation according to ~~any of the claims from 1 to 7~~ claim 1, comprising 1 MIU/ml of interferon-beta, 54.6 mg/ml of mannitol, 0.5 mg/ml of albumin in a solution of 0.01 M acetate buffer at pH 3.5.

9. Process for the preparation of a liquid pharmaceutical formulation according to ~~any of the claims from 1 to 8~~ claim 1, comprising the dilution of interferon-beta with a solution of excipients.

10. A container hermetically sealed in sterile conditions comprising the liquid pharmaceutical formulation according to ~~any of the claims from 1 to 8~~ claim 1 and appropriate for storage prior to use.

a
a

Add 74